Oruka Therapeutics Posts $0.63 Q3 GAAP Loss Per Share, Matching Estimates

Your call?🐂 Bullish🐻 Bearish

Cash, cash equivalents and marketable securities totaled $1.2 billion as of Sept. 30, 2026. Quarterly operating cash use was $44.3 million, compared with $21.6 million a year earlier.